|1.||Szabó, Csaba: 20 articles (07/2007 - 01/2002)|
|2.||Watkins, Michael T: 8 articles (07/2010 - 01/2005)|
|3.||Albadawi, Hassan: 7 articles (07/2010 - 01/2005)|
|4.||Virág, László: 6 articles (01/2014 - 02/2002)|
|5.||Liaudet, Lucas: 6 articles (12/2002 - 01/2002)|
|6.||Conrad, Mark F: 5 articles (07/2010 - 08/2005)|
|7.||Cambria, Richard P: 5 articles (10/2009 - 01/2005)|
|8.||Entabi, Fateh: 5 articles (10/2009 - 04/2005)|
|9.||Szabo, Csaba: 5 articles (06/2008 - 02/2002)|
|10.||Szabó, C: 5 articles (09/2006 - 03/2001)|
09/01/2006 - "PJ34 (25 mg kg(-1)) reduced the infarct volume (-26%) and improved neurological deficit, 24 h after ischemia. "
10/01/2006 - "The purpose of this study was to determine whether intra-muscular (IM) administration of PJ34, a potent inhibitor of PARP, after the onset of acute hindlimb ischemia (post hoc) modulates the local production of inflammatory mediators during ischemia/reperfusion (I/R). "
08/01/2013 - "Ischemia was produced by intraluminal occlusion of the left middle cerebral artery and treated with vehicle, rt-PA (10 mg/kg, i.v., 6 h after occlusion) or rt-PA plus PJ34 (3, 6 or 12 mg/kg, i.p., at ischemia onset and 4 h later). "
08/01/2009 - "Normal saline was administered to 25 untreated control mice and PJ34 to 21 mice before and immediately after thoracic aortic ischemia-reperfusion. "
04/01/2009 - "Behavioral tests performed 6 to 8 weeks after ischemia showed deficits in spatial memory and learning that were lessened by the PJ34 treatment. "
01/01/2013 - "According to previous findings observed by confocal imaging of fixed cells, PJ-34 exclusively eradicated cancer cells with multi-centrosomes without impairing normal cells undergoing mitosis with two centrosomes and bi-focal spindles. "
08/01/2015 - "In vivo, the tumor inhibition rates were 53.5%, 61.4% and 82.6% in PJ34, SAHA and PJ34+SAHA groups, respectively. "
08/01/2015 - "The nude mice bearing subcutaneous HepG2 tumors were administered different groups of drugs (10 mg/kg PJ34, 25 mg/kg SAHA, 10 mg/kg PJ34+25 mg/kg SAHA), and the inhibition rates of tumor growth were compared between groups. "
01/01/2014 - "Finally, the combination treatment of TRAIL and PJ34 significantly reduced tumor growth in vivo when compared to treatment with each agent alone. "
01/01/2013 - "These results linked for the first time the recently detected exclusive cytotoxic activity of PJ-34 in human cancer cells with extra-centrosomes de-clustering in mitosis, and mitotic failure leading to cell death. "
11/01/2001 - "We have recently demonstrated the efficacy of PJ34, a novel, potent phenanthridinone derivative PARP inhibitor, in rodent models of diabetic vascular dysfunction and stroke. "
08/01/2013 - "To conclude, the PARP inhibitor PJ34 makes rt-PA safer in experimental ischemic stroke. "
03/01/2001 - "Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke."
10/01/2013 - "Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice."
11/01/2001 - "Delaying the start of PJ34 administration in the colitis model conferred significant protective effects, while in the arthritis model the post-treatment paradigm lacked protective effects. "
01/01/2009 - "Recent studies in a variety of rodent models of experimental colitis by using PJ-34, a potent poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, support the concept that the marked beneficial effect of PJ-34 can be exploited to treat human inflammatory diseases. "
11/01/2001 - "PJ34 treatment (oral gavage) induced a significant suppression of the inflammatory response in dextran sulfate colitis, multiple low dose streptozotocin diabetes and cyclophosphamide-accelerated autoimmune diabetes in the non-obese diabetic mice, and reduced the degree of mononuclear cell infiltration into the iris in an endotoxin-induced uveitis model. "
|5.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
01/01/2015 - "Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells."
01/01/2015 - "Since PJ-34 has been tested in clinical trials for the treatment of solid tumors, our results suggest that some ATLL patients may be good candidates to benefit from PJ-34 therapy."
01/01/2015 - "In this study, we found that a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), PJ-34, is very effective in activating S/G2M cell cycle checkpoints, resulting in permanent cell cycle arrest and reactivation of p53 transcription functions and caspase-3-dependent apoptosis of HTLV-I-transformed and patient-derived ATLL tumor cells. "
|1.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|3.||Adenosine Triphosphate (ATP)
|9.||Poly Adenosine Diphosphate Ribose
|1.||Drug Therapy (Chemotherapy)
|2.||Heart Transplantation (Grafting, Heart)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Photochemotherapy (Photodynamic Therapy)